Professor Munitta Muthana

School of Medicine and Population Health

School Director of One University

Professor of Immuno-oncology

Munitta Muthana
Profile picture of Munitta Muthana
m.muthana@sheffield.ac.uk
+44 114 215 9057
D Floor, The Medical School

Full contact details

Professor Munitta Muthana
School of Medicine and Population Health
D Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I joined the University of Sheffield in 2002 as a post-doctoral scientist in the Immunobiology Research Unit. From 2005 I held a research position in the Tumour Targeting Group where I was awarded funding as an independent researcher from the Prostate Cancer Charity (2007) and the Medical Research Council (2010). In 2011, I was appointed as non-clinical lecturer and I am now Senior Lecturer in the Department of Oncology and Metabolism.

Nanobug Oncology Sheffield
Nanobug Oncology Sheffield

Current PhD opportunities:

  •  
Research interests

Our tea. ‘Nanobug Oncology Sheffield’ (@Nanobug_Shef) focuses on developing state-of-the-art methods to target anticancer therapies to tumours. For example, we have devised a way to use macrophages as ‘trojans’ to deliver large quantities of cancer-killing virus to both primary and secondary tumours simultaneously (). We are currently developing innovative nanomedicine platforms to improve the targeting of drugs to tumours so that healthy tissue remains unharmed. We have used these platforms to protect and deliver oncolytic viruses via the bloodstream so that advanced metastatic cancers can be treated. These include liposomes, nanohydrogels, silk fibroin, extracellular vesicles, and magnetic nanoparticles. For the latter, we recently demonstrated that iron particles purified from magnetotactic bacteria were able to shield viruses and guide them to tumours in models of breast cancer. 

Current projects

  • Targeting novel oncolytic viruses to tumours.
  • Using nanomagnet technology to improve tumour targeting.
  • Developing novel magnetic devices for cancer.
  • Using a novel microfluidic device for producing silk fibroin nanoparticles.
  • Developing nanoplatforms for targeting oncolytic viruses.
  • Characterisation of infiltrating subsets of monocytes/macrophages in the tumour microenvironment.
  • Using immune checkpoint inhibitors in combination with oncolytic viruses.
Publications

Show: Featured publications All publications

Journal articles

  • Kim T, Johnston J, Castillo-Lluva S, Cimas FJ, Hamby S, Cardiogenics Consortium* T, Gonzalez-Moreno S, Villarejo-Campos P, Goodall AH, Velasco G , Ocana A et al (2022) . Theranostics, 12(8), 3584-3600.
  • Howard FHN, Al‐Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, Pockley AG, Conner J, Nohl JF, Allwood DA , Collado‐Rojas C et al (2022) . Small, 18(13).
  • Iscaro A, Jones C, Forbes N, Mughal A, Howard FN, Janabi HA, Demiral S, Perrie Y, Essand M, Weglarz A , Cruz LJ et al (2022) . Nanomedicine: Nanotechnology, Biology and Medicine, 40.
  • Canuas-Landero VG, George CN, Lefley DV, Corness H, Muthana M, Wilson C & Ottewell PD (2021) . Frontiers in Endocrinology, 12.
  • Kwan A, Winder N & Muthana M (2021) . Viruses, 13(6).
  • George C, Lefley D, Canuas-Landero V, Tulotta C, Corness H, Wilson C, Muthana M & Ottewell P (2021) . Bone Reports, 14, 101024-101024.
  • Taher Z, Legge C, Winder N, Lysyganicz P, Rawlings A, Bryant H, Muthana M & Staniland S (2021) . Pharmaceutics, 13(3).
  • Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) . Journal for ImmunoTherapy of Cancer, 9(3).
  • Sier VQ, de Vries MR, van der Vorst JR, Vahrmeijer AL, van Kooten C, Cruz LJ, de Geus-Oei L-F, Ferreira V, Sier CFM, Alves F & Muthana M (2021) . International Journal of Molecular Sciences, 22(2).
  • Iscaro A, Howard NF & Muthana M (2019) . Current Pharmaceutical Design, 25(17), 1962-1979.
  • Song W, Gregory DA, Al-Janabi H, Muthana M, Cai Z & Zhao X (2019) . International Journal of Pharmaceutics, 555, 322-336.
  • Song W, Muthana M, Mukherjee J, Falconer RJ, Biggs CA & Zhao X (2017) . ACS Biomaterials Science & Engineering, 3(6), 1027-1038.
  • Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U , Veale D et al (2015) . Proceedings of the National Academy of Sciences, 112(37), 11618-11623.
  • Muthana M, Kennerley AJ, Hughes R, Fagnano E, Richardson J, Paul M, Murdoch C, Wright F, Payne C, Lythgoe MF , Farrow N et al (2015) . Nature Communications, 6.
  • Tazzyman S, Murdoch C, Yeomans J, Harrison J & Muthana M (2014) . Hypoxia, 2, 185-196.

Conference proceedings

  • Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) . Rheumatology, Vol. 53(suppl_1) (pp i147-i147)

All publications

Journal articles

  • Oliveira F, Pereira J, Neca C, Mansor MH, Gao Z, Muthana M & Duarte ARC (2025) . Journal of Drug Delivery Science and Technology, 114, 107517-107517.
  • Mansor MH, Williamson L, Ludwikowski D, Howard F & Muthana M (2025) . Physchem, 5(3).
  • Stewart G, Tazzyman S, Sun Y, Andrews RE, Harrison J, Lath D, Down J, Robinson G, Wang X, Muthana M , Chantry AD et al (2025) . Leukemia, 39(6), 1449-1463.
  • Gao Z, Mansor MH, Howard F, MacInnes J, Zhao X & Muthana M (2025) . Nanomaterials, 15(3).
  • Mansor MH, Gao Z, Howard F, MacInnes J, Zhao X & Muthana M (2025) . Pharmaceutics, 17(1).
  • Kwan A, Mcdermott-Brown I & Muthana M (2024) . Viruses, 16(8).
  • Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C , Junker-Jensen A et al (2024) . Journal for ImmunoTherapy of Cancer, 12(7).
  • Rahman MM, Wells G, Rantala JK, Helleday T, Muthana M & Danson SJ (2024) . Expert Review of Clinical Immunology, 20(8), 821-838.
  • Kwan A, Stark K, Allen R, Ottewell P & Muthana M (2024) . Medical Research Archives, 12(6).
  • Hapuarachi B, Danson S, Wadsley J & Muthana M (2023) . Frontiers in Immunology, 14.
  • Egerton K, Mitchell TA, Gravells P, Katse R, Fisher M, Muthana M, Eyers CE, Eyers PA & Bryant HE (2023) . ESMO Open, 8(1), 101664-101664.
  • Gao Z, Mansor MH, Winder N, Demiral S, Maclnnes J, Zhao X & Muthana M (2023) . Pharmaceutics, 15(7).
  • Winder N, Ashraf Z, Gohar S, Baalbaki N, Cork M, Danby S & Muthana M (2023) . Frontiers in Virology, 3.
  • Tazzyman S, Stewart GR, Yeomans J, Linford A, Lath D, Conner J, Muthana M, Chantry AD & Lawson MA (2023) . Viruses, 15(3).
  • Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S , Kennerley AJ et al (2023) . Nanotheranostics, 7(1), 102-116.
  • Winder N, Gohar S & Muthana M (2022) . Viruses, 14(12).
  • Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al (2022) . Future Pharmacology, 2(4), 444-459.
  • Howard FHN, Kwan A, Winder N, Mughal A, Collado-Rojas C & Muthana M (2022) . Viruses, 14(7).
  • Howard F, Conner J, Danson S & Muthana M (2022) . Frontiers in Molecular Biosciences, 9.
  • Kim T, Johnston J, Castillo-Lluva S, Cimas FJ, Hamby S, Cardiogenics Consortium* T, Gonzalez-Moreno S, Villarejo-Campos P, Goodall AH, Velasco G , Ocana A et al (2022) . Theranostics, 12(8), 3584-3600.
  • Howard FHN, Al‐Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, Pockley AG, Conner J, Nohl JF, Allwood DA , Collado‐Rojas C et al (2022) . Small, 18(13).
  • Iscaro A, Jones C, Forbes N, Mughal A, Howard FN, Janabi HA, Demiral S, Perrie Y, Essand M, Weglarz A , Cruz LJ et al (2022) . Nanomedicine: Nanotechnology, Biology and Medicine, 40.
  • Canuas-Landero VG, George CN, Lefley DV, Corness H, Muthana M, Wilson C & Ottewell PD (2021) . Frontiers in Endocrinology, 12.
  • Kwan A, Winder N & Muthana M (2021) . Viruses, 13(6).
  • Kim T, Johnston J, Felipe FJC, Hamby S, Castillo-Lluva S, Goodall AH, Velasco G, Ocana A, Muthana M & Kiss-Toth E (2021) .
  • George C, Lefley D, Canuas-Landero V, Tulotta C, Corness H, Wilson C, Muthana M & Ottewell P (2021) . Bone Reports, 14, 101024-101024.
  • Taher Z, Legge C, Winder N, Lysyganicz P, Rawlings A, Bryant H, Muthana M & Staniland S (2021) . Pharmaceutics, 13(3).
  • Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) . Journal for ImmunoTherapy of Cancer, 9(3).
  • Deng S, Iscaro A, Zambito G, Mijiti Y, Minicucci M, Essand M, Lowik C, Muthana M, Censi R, Mezzanotte L & Di Martino P (2021) . Nanomaterials, 11(1).
  • Sier VQ, de Vries MR, van der Vorst JR, Vahrmeijer AL, van Kooten C, Cruz LJ, de Geus-Oei L-F, Ferreira V, Sier CFM, Alves F & Muthana M (2021) . International Journal of Molecular Sciences, 22(2).
  • Aldughaim MS, Muthana M, Alsaffar F & Barker MD (2021) . Molecules, 26(1).
  • Kwan A, Winder NJ, Atkinson E, Al-Janabi HH, Allen RJ, Hughes R, Moamin MR, Louie R, Evans D, Hutchinson M , Capper DT et al (2020) . Mol Cancer Ther.
  • George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C & Ottewell P (2020) . Journal of Bone Oncology, 25.
  • Howard F & Muthana M (2020) . Nanomedicine, 15(1), 93-110.
  • Niespolo C, Shologu Z, Satam S, Iscaro A, Muthana M, Socorro S, Wilson HL & Kiss-Toth E (2019) . European Urology Supplements, 18(8), e3090-e3091.
  • Narayanan P, Martinez Campesino L, Kim T, Muthana M, Wilson HL & Kiss-Toth E (2019) . European Urology Supplements, 18(8), e3060-e3060.
  • Iscaro A, Howard NF & Muthana M (2019) . Current Pharmaceutical Design, 25(17), 1962-1979.
  • Dorris ER, Tazzyman SJ, Moylett J, Ramamoorthi N, Hackney J, Townsend M, Muthana M, Lewis MJ, Pitzalis C & Wilson AG (2019) . The Journal of Immunology, 202(4), 1069-1078.
  • Song W, Gregory DA, Al-Janabi H, Muthana M, Cai Z & Zhao X (2019) . International Journal of Pharmaceutics, 555, 322-336.
  • Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) . Blood, 132(Supplement 1), 3213-3213.
  • Song W, Muthana M, Mukherjee J, Falconer RJ, Biggs CA & Zhao X (2017) . ACS Biomaterials Science & Engineering, 3(6), 1027-1038.
  • Rahat MA, Coffelt SB, Granot Z, Muthana M & Amedei A (2016) . Mediators Inflamm, 2016.
  • Colley HE, Muthana M, Danson SJ, Jackson LV, Brett ML, Harrison J, Coole SF, Mason DP, Jennings LR, Wong M , Tulasi V et al (2015) . Journal of Medicinal Chemistry, 58(23), 9309-9333.
  • Hawtree S, Muthana M, Wilkinson JM, Akil M & Wilson AG (2015) . Human Molecular Genetics, 24(19), 5367-5377.
  • Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U , Veale D et al (2015) . Proceedings of the National Academy of Sciences, 112(37), 11618-11623.
  • Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M , Gonzalez-Angulo AM et al (2015) . Cancer Research, 75(17), 3479-3491.
  • Muthana M, Kennerley AJ, Hughes R, Fagnano E, Richardson J, Paul M, Murdoch C, Wright F, Payne C, Lythgoe MF , Farrow N et al (2015) . Nature Communications, 6.
  • Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) . Rheumatology, 53(suppl_1), i85-i85.
  • Ellam T, Hameed A, ul Haque R, Muthana M, Wilkie M, Francis SE & Chico TJA (2014) . PLoS One, 9(2), e88767.
  • Tazzyman S, Murdoch C, Yeomans J, Harrison J & Muthana M (2014) . Hypoxia, 2, 185-196.
  • Chen Y-Y, Brown NJ, Jones R, Lewis CE, Mujamammi AH, Muthana M, Seed MP & Barker MD (2014) . Angiogenesis, 17(1), 207-219.
  • Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) . Annals of the Rheumatic Diseases, 72, A165-A166.
  • Hardy WJ, Aynsley S, Fearon U, Veale D, Wilson AG & Muthana M (2013) . Annals of the Rheumatic Diseases, 72, A199-A199.
  • Hawtree S, Muthana M & Wilson AG (2013) . Biochem Soc Trans, 41(3), 783-788.
  • Mehta P, Holder S, Fisher B, Vincent T, Nadesalingam K, Maciver H, Shingler W, Bakshi J, Hassan S, D'Cruz D , Chan A et al (2013) . Rheumatology, 52(suppl 1), i56-i94.
  • Fleischmann R, van Vollenhoven RF, Smolen J, Emery P, Florentinus S, Rathmann S, Kupper H, Kavanaugh A, Taylor P, Genovese M , Keystone EC et al (2013) . Rheumatology, 52(suppl 1), i44-i55.
  • Muthana M, Rodrigues S, Chen Y-Y, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F & Lewis CE (2013) . Cancer Res, 73(2), 490-495.
  • Muthana M, Richardson J, Rodrigues S & Lewis C (2013) . BIO-PROTOCOL, 3(13).
  • Hardy WJ, Aynsley S, Fearon U, Veale D, Wilson AG & Muthana M (2013) HYPDXIA-INDUCIBLE FACTOR 2A IS PREFERENTIALLY EXPRESSED BY M2-LIKE SYNOVIAL MACROPHAGES IN RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 72, 199-199.
  • Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS FIBROBLASTS-LIKE SYNOVIOCYTES. ANNALS OF THE RHEUMATIC DISEASES, 72, 165-166.
  • Murdoch C, Aziz HA, Fang H-Y, Jezan H, Musaid R & Muthana M (2011) . J Ethnopharmacol, 138(3), 780-787.
  • Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, Lewis CE & Byrne HM (2011) . Cancer Res, 71(8), 2826-2837.
  • Coffelt SB, Chen Y-Y, Muthana M, Welford AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M & Lewis CE (2011) . J Immunol, 186(7), 4183-4190.
  • Muthana M, Giannoudis A, Scott SD, Fang H-Y, Coffelt SB, Morrow FJ, Murdoch C, Burton J, Cross N, Burke B , Mistry R et al (2011) . Cancer Res, 71(5), 1805-1815.
  • Muthana M, Multhoff G & Pockley AG (2010) . Int J Hyperthermia, 26(3), 247-255.
  • Murdoch C, Muthana M, Coffelt SB & Lewis CE (2008) . Nat Rev Cancer, 8(8), 618-631.
  • Muthana M, Scott SD, Farrow N, Morrow F, Murdoch C, Grubb S, Brown N, Dobson J & Lewis CE (2008) . Gene Ther, 15(12), 902-910.
  • Pockley AG, Muthana M & Calderwood SK (2008) . Trends Biochem Sci, 33(2), 71-79.
  • Pockley AG, Fairburn B, Mirza S, Slack LK, Hopkinson K & Muthana M (2007) . Methods, 43(3), 238-244.
  • Slack LK, Muthana M, Hopkinson K, Suvarna SK, Espigares E, Mirza S, Fairburn B & Pockley AG (2007) . Cell Stress Chaperones, 12(1), 71-82.
  • Mirza S, Muthana M, Fairburn B, Slack LK, Hopkinson K & Pockley AG (2006) . Cell Stress Chaperones, 11(4), 364-378.
  • Fairburn B, Muthana M, Hopkinson K, Slack LK, Mirza S, Georgiou AS, Espigares E, Wong C & Pockley AG (2006) . Biochimie, 88(9), 1165-1174.
  • Muthana M, Fairburn B, Mirza S, Slack LK, Hopkinson K & Pockley AG (2006) . Immunobiology, 211(5), 391-402.
  • Muthana M, Slack LK, Hopkinson K, Espigares E, Fairburn B, Mirza S & Pockley AG (2005) Gp96 prolongs rat cardiac allograft survival and modifies rejection-associated inflammatory events. IMMUNOLOGY, 116, 107-107.
  • Mirza S, Muthana M, Slack LK, Hopkinson K, Fairburn B & Pockley AG (2005) The stress protein gp96 does not activate rat bone marrow-derived dendritic cells. IMMUNOLOGY, 116, 98-98.
  • Murdoch C, Muthana M & Lewis CE (2005) . J Immunol, 175(10), 6257-6263.
  • Pockley AG & Muthana M (2005) . Contrib Nephrol, 148, 122-134.
  • Muthana M, Fairburn B, Mirza S, Slack LK & Pockley AG (2004) . J Immunol Methods, 294(1-2), 165-179.
  • Carlring J, Shaif-Muthana M, Sisley K, Rennie IG & Murray AK (2003) . Immunology, 109(1), 41-48.
  • Molife R, Muthana M, Wilkinson D, Hedley S, Browne S, Brookes R, Murray A, Rennie I & Lorigan P (2002) Pilot study: Immunisation with melanoma associated peptides and GM-CSF in HLA-A2 patients with metastatic melanoma.. BRIT J CANCER, 86, S115-S115.
  • Shaif-Muthana M, McIntyre C, Sisley K, Rennie I & Murray A (2000) Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.. Cancer Res, 60(22), 6441-6447.

Book chapters

  • Nutter Howard FH, Iscaro A & Muthana M (2022) , Systemic Drug Delivery Strategies (pp. 211-230). Elsevier
  • Hughes R & Muthana M (2014) , Tumor Immunology and Immunotherapy (pp. 43-62). Oxford University Press
  • Hughes R, Fang H-Y, Muthana M & Lewis CE (2011) , Tumour-Associated Macrophages (pp. 17-29). Springer New York
  • Pockley AG & Muthana M (2007) , Heat Shock Proteins: Potent Mediators of Inflammation and Immunity (pp. 309-320). Springer Netherlands
  • Pockley AG & Muthana M (2007) , Cell Stress Proteins (pp. 377-395). Springer New York
  • H.N. Howard F, Gao Z, Bin Mansor H, Yang Z & Muthana M () , Biomedical Engineering IntechOpen
  • Iscaro A, H.N. Howard F, Yang Z, Jenkins F & Muthana M () , Liposomes - Recent Advances, New Perspectives and Applications IntechOpen

Conference proceedings

  • Wang X, Sun Y, Stewart G, Chantry A, Muthana M & Lawson M (2025) Development of In-vivo Murine Plasmacytoma Models for Multiple Myeloma. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 206
  • Sheridan K, Doris E, Pimenta M, Falkov J, Fisher M, Muthana M, Shields D, Mains R, Eipper B, Buckley C & Wilson A (2024) Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS & RHEUMATOLOGY, Vol. 76 (pp 1864-1865)
  • Rahman MM, Wells G, Rantala J, Helleday T, Muthana M & Danson S (2023) . Annals of Oncology, Vol. 34 (pp S1177-S1177)
  • Al-janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) . Cancer Research, Vol. 81(13_Supplement) (pp 2797-2797)
  • Al-Janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) Changes in the phenotype of macrophages and CD8+T Cells in the perivascular niche of prostate tumours following androgen deprivation.. CANCER RESEARCH, Vol. 81(13)
  • Danson SJ, Conner J, Edwards JG, Blyth KG, Fisher PM, Muthana M, Salawu A, Taylor F, Hodgkinson E, Joyce P , Roman J et al (2020) . Lung Cancer, Vol. 150 (pp 145-151)
  • AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) . Cancer Research, Vol. 79(13_Supplement)
  • Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) . Cancer Research, Vol. 79(13_Supplement)
  • Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) . Tumor Biology
  • Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) . Cancer Research, Vol. 79(13_Supplement)
  • Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) . Tumor Biology
  • AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) . Immunology
  • Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
  • AL-Janabi H, Conner J, Taher Z, Staniland S & Muthana M (2018) . European Journal of Cancer, Vol. 92 (pp S4-S4)
  • Seehra RS, Wharton S, Heath P, Ince P, Muthana M, Garwood C & Simpson J (2018) Hypoxia-induced changes in astrocytes and their role in the formation of age-associated white matter lesions. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, Vol. 44 (pp 17-18)
  • Muthana M, Murphy E, Kwan A, Winder N & Conner J (2017) . Cancer Research, Vol. 77(13_Supplement) (pp 2938-2938)
  • Dorris E, Creevey K, Moylett J, Tazzyman S, Muthana M & Wilson AG (2017) The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages. ARTHRITIS & RHEUMATOLOGY, Vol. 69
  • Dorris ER, Creevey K, Moran C, Muthana M & Wilson AG (2016) . Annals of the Rheumatic Diseases, Vol. 75 (pp 107-107)
  • Tazzyman S, Muthana M, Harrison J, Lewis C, Conner J & Chantry A (2015) . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e14035-e14035)
  • Hardy W, Wright F, Hawtree S, Fearon U, Veale D, Perretti M, Wilson A & Muthana M (2014) . Annals of the Rheumatic Diseases, Vol. 73 (pp 174-174)
  • Muthana M, Davies H, Khetan S, Wright F, Hawtree S, Ciani B & Wilson A (2014) . Annals of the Rheumatic Diseases, Vol. 73 (pp 361-361)
  • Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) . Annals of the Rheumatic Diseases, Vol. 73 (pp 517-517)
  • Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) . Rheumatology, Vol. 53(suppl_1) (pp i147-i147)
  • Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 85-85)
  • Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 147-147)
  • Albloui FS, Muthana M, Wilson AG & Grabowski PS (2014) Acidification enhances acid sensing protein and matrix metalloproteinase expression in human rheumatoid fibroblast like synoviocytes. Annals of the Rheumatic Diseases, Vol. 73(Supplement 2) (pp 511-511)
  • Davies H, Muthana M, Khetan S, Adeleke G, Hawtree S, Morrow F, Ciani B & Wilson AG (2013) . Annals of the Rheumatic Diseases, Vol. 72 (pp A190-A190)
  • Albloui FS, Muthana M, Wilson AG & Grabowski PS (2013) . Annals of the Rheumatic Diseases, Vol. 72 (pp A812-A812)
  • Albloui FS, Muthana M, Wilson AG & Grabowski PS (2013) TISSUE LOCALISATION OF ACID SENSING PROTEINS IN SYNOVIAL BIOPSIES FROM PATIENTS WITH RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 812-812)
  • Davies H, Muthana M, Khetan S, Adeleke G, Hawtree S, Morrow F, Ciani B & Wilson AG (2013) THE ROLE OF C5ORF30 IN RHEUMATOID ARTHRITIS PATHOGENESIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 190-190)
  • Muthana M, Davies H, Khetan S, Adeleke G, Hawtree S, Wright F, Ciani B, Akil M & Wilson AG (2013) The biological role of C5orf30 in rheumatoid arthritis pathogenesis. IMMUNOLOGY, Vol. 140 (pp 45-45)
  • Muthana M, Davies H, Khetan S, Adeleke GA, Hawtree S & Wilson AG (2013) Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1232-S1233)
  • Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1035-S1036)
  • Muthana M, Davies H, Khetan S, Adeleke G, Hawtree S, Tazzyman S, Morrow F, Ciani B & Wilson G (2013) BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 52 (pp 50-50)
  • Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) Investigation of the role of histone deacetylases in rheumatoid arthritis synovial fibroblasts. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 94(5) (pp A3-A3)
  • Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 52 (pp 79-80)
  • Aynsley S, Hardy J, Veale D, Fearon U, Wilson G & Muthana M (2013) MACROPHAGES IN HYPOXIC RHEUMATOID JOINTS PREFERENTIALLY EXPRESS HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR-2. RHEUMATOLOGY, Vol. 52 (pp 78-78)
  • Muthana M, Khetan S, Adeleke GA, Tazzyman S, Aynsley S, Morrow F, Hawtree S, Ciani B & Wilson AG (2012) Biological Roles of C5orf30 in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
  • Grabowski PS, Muthana M & Wilson AG (2012) . BONE, Vol. 50 (pp S191-S191)
  • Aynsley S, Fearon U, Wilson AG & Muthana M (2012) Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
  • Khetan S, Muthana M & Wilson AG (2011) C5orf30 a Candidate Susceptibility Gene in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 63(10) (pp S719-S719)
  • Muthana M, Giannoudis A, Scott SD, Mistry R, Murdoch C, Coffelt S, Georgeopolous L, Hamdy F, Brown N, Maitland N & Lewis CE (2010) . DRUG DISCOVERY TODAY, Vol. 15(23-24) (pp 1097-1098)
  • Muthana M, Giannoudis A, Scott SD, Mistry R, Murdoch C, Georgeopolous L, Hamdy F, Brown N, Maitland N & Lewis CE (2010) Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours. HUMAN GENE THERAPY, Vol. 21(4) (pp 488-488)
  • Muthana M, Scott S, Farrow N, Murdoch C & Lewis C (2007) Magnetite nanoparticle-loaded macrophages enhance gene delivery to tumours. IMMUNOLOGY, Vol. 120 (pp 82-82)
  • Muthana M, Giannoudis A, Scott SD, Burke B, Mistry R, Hamdy F, Brown N, Maitland N & Lewis CE (2006) Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors. CANCER RESEARCH, Vol. 66(8)

Other

  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .
  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .
  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .
  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .

Preprints

  • Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, De Bono J, Nunns H, Bailey C , Juncker-Jensen A et al (2024) , Cold Spring Harbor Laboratory.
Teaching interests

I teach Immunology on the MBChB course and I am module lead for Phase 2a immunology. I also deliver the cell-based therapies, Gene Therapy, Animal models in Research and Tumour Immunology lectures for the medical school MSc. Molecular Medicine, MSc. Translational Oncology, MSc. Advanced Cell and Gene therapy, MSc Translational Neuroscience.

Professional activities and memberships
  • American Association of Cancer Research (AACR).
  • British Society of Immunology (BSI).
  • European Macrophage and Dendritic Cell Society and British Society of Immunology.